Someone mentioned a compendium listing where products can be used off label with other products and will be approved by insurance. Could Oncovir be looking to get a compendium listing when DCVax-L is approved and not be required to do further trials, or have further expenses, at all. Both companies after establishing revenue streams may want further trials in other cancers, or raise money in other ways to do it sooner, but the point is on approval of DCVax-L the door may be open to using Poly-ICLC, and getting insurance coverage for it immediately.
Finally there is the thought that once we have an approval and a substantially higher share price Oncovir might seriously consider being acquired by NWBO for stock, or perhaps cash, or a mix of both. LP clearly seems to be looking at the possibility of bringing many things together, some she already owns, but they all could work together and achieve a whole that was dramatically bigger than the sum of its parts. I certainly don't know that this is the plan, or that LP intends to sell out to the first offeror, but it looks more to me that she's looking to build something than to tear it apart.
Gary
News 
Market Data 
Discover 
AI
